CliffBio
biologic

VYJUVEK

beremagene geperpavec-svdt

Loss of exclusivityMay 2035projected — 12-year biologic exclusivity estimate
CompanyKrystal Biotech →See this company's full patent-cliff portfolio

Drug detail

Brand nameVYJUVEK
Active ingredientberemagene geperpavec-svdt
Strength5.0x10^9 PFU/mL
Dosage formGel
RouteTopical
ModalityBiologic
FDA approvalMay 2023
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

VYJUVEK patent cliff — loss of exclusivity May 2035 | CliffBio